行情

CELG

CELG

新基医药
NASDAQ

实时行情|Nasdaq Last Sale

110.02
0.00
0.00%
盘后: 109.65 -0.37 -0.34% 18:52 11/15 EST
开盘
110.23
昨收
110.02
最高
110.26
最低
109.71
成交量
406.37万
成交额
--
52周最高
110.70
52周最低
58.59
市值
782.68亿
市盈率(TTM)
13.72
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CELG 新闻

  • FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition
  • MarketWatch.1小时前
  • Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
  • Investor's Business Daily.2小时前
  • UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug
  • Reuters.2小时前
  • FTC on board with Bristol-Myers/Celgene tie-up on Otezla sale
  • Seeking Alpha - Article.2小时前

更多

所属板块

制药
+1.25%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

CELG 简况

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
展开

Webull提供Celgene Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。